Ongoing clinical trials of human immunodeficiency virus latency-reversing and immunomodulatory agents

Héloïse M. Delagrèverie, Constance Delaugerre, Sharon R. Lewin, Steven G. Deeks, Jonathan Z. Li

Research output: Contribution to journalReview ArticleResearchpeer-review

64 Citations (Scopus)


In chronic human immunodeficiency virus (HIV)-1 infection, long-lived latently infected cells are the major barrier to virus eradication and functional cure. Several therapeutic strategies to perturb, eliminate, and/or control this reservoir are now being pursued in the clinic. These strategies include latency reversal agents (LRAs) designed to reactivate HIV-1 ribonucleic acid transcription and virus production and a variety of immune-modifying drugs designed to reverse latency, block homeostatic proliferation, and replenish the viral reservoir, eliminate virus-producing cells, and/or control HIV replication after cessation of antiretroviral therapy. This review provides a summary of ongoing clinical trials of HIV LRAs and immunomodulatory molecules, and it highlights challenges in the comparison and interpretation of the expected trial results.

Original languageEnglish
Article numberofw189
JournalOpen Forum Infectious Diseases
Issue number4
Publication statusPublished - 2016


  • Anti-HIV agents
  • Clinical trial
  • HIV-1
  • Latency-reversing agents
  • Viral reservoir

Cite this